This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D15.1 (benign neoplasm of heart) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Cardiac myxoma, cardiac lipoma, cardiac rhabdomyoma, papillary fibroelastoma, cardiac fibroma |
| C. Adult onset | Cardiac myxoma is most common in adults in their 30s–60s and occurs 2–3 times more often in women. Sporadic myxomas mainly present after middle age, while those of hereditary Carney complex also appear in young adults. |
| 1. History | First described by Colombo in 1559; first successful surgical resection by Crafoord in 1954. Diagnosis rates rose sharply with the spread of echocardiography in the late 20th century. |
| 2. Causes | Most cases are sporadic (~95%). The hereditary form (Carney complex) is associated with PRKAR1A gene variants. Originates from primitive multipotent mesenchymal cells of the endocardium. |
| 3. Genetics | Carney complex: inactivating variants of the PRKAR1A gene at 17q22-24. Autosomal dominant inheritance; accounts for about 7% of familial myxomas. |
| 4. General epidemiology | The most common benign tumor among primary cardiac tumors. Incidence 0.5–1 per million per year. 75% originate in the left atrium, 25% in the right atrium. Female predominance. |
| 5. Pathophysiology | Neoplastic proliferation of multipotent mesenchymal cells of the endocardium around the foramen ovale. Angiogenesis within a myxoid stroma, carrying a risk of tumor embolism. |
| 6. Symptoms | Dyspnea (64.5%), chest pain (39.5%), arrhythmia (35.5%). Systemic embolism (stroke, peripheral embolism), constitutional symptoms (fever, weight loss, fatigue). |
| 7. Signs | Tumor 'plop' on auscultation, murmur mimicking mitral stenosis, hemodynamic changes with change of position. Clubbing of the fingers and toes. |
| 8. Screening | Transthoracic echocardiography is the first-line screen. Regular echocardiographic follow-up in patients with Carney complex. Genetic testing recommended in familial cases. |
| 9. Diagnosis | Echocardiography (including TEE), cardiac CT and MRI, tissue biopsy. A mobile mass located adjacent to the foramen ovale is characteristic. |
| 10. Treatment | Complete surgical resection is the standard treatment. Resection under cardiopulmonary bypass; simple tumor removal suffices in 65.8%. Reoperation considered for recurrence. |
| 11. Prognosis | Good long-term prognosis after surgery. Sporadic recurrence rate 1–3%. Recurrence rate up to 44% in Carney complex. Early surgery is key. |
| 12. Prevention | Regular echocardiographic follow-up for hereditary Carney complex. Early identification of at-risk individuals by PRKAR1A genetic testing. |
| 13. References | Diagnosis and Surgical Treatment Outcomes of Cardiac Myxoma: Twenty Years of Data at a Single Institution … and 9 other papers |
The first systematic description of cardiac tumors dates back to the Italian anatomist Realdo Colombo (Realdus Columbus) in 1559. He recorded an intracardiac mass discovered incidentally at autopsy but did not grasp the clinical significance of the lesion at the time. Over the following centuries, sporadic case reports accumulated in the European medical literature, but antemortem diagnosis was considered virtually impossible.
With the advance of pathology in the early 20th century, cardiac myxoma began to be classified as the most common benign neoplasm among primary cardiac tumors. In the 1930s, Ernst systematically described the histological features of myxoma, identifying its distinctive structure of stellate cells scattered in a gelatinous myxoid stroma. Even at this time, however, surgical treatment was hardly possible to attempt.
A landmark turning point in the history of cardiac myxoma treatment was the first successful resection of a left atrial myxoma using cardiopulmonary bypass by Clarence Crafoord of Sweden in 1954. The success of this operation was also an important milestone in the development of cardiac surgery as a whole. Subsequently, Kirklin, Harken and others in the United States reported similar operations, and surgical resection began to become established as the standard treatment.
A revolution in diagnosis came with the clinical application of echocardiography in the 1960s. Early M-mode echocardiography could detect abnormal echoes oscillating behind the mitral valve, and the introduction of two-dimensional (2D) echocardiography in the 1970s made it possible to visualize the shape and attachment site of intra-atrial masses in real time. As a result, antemortem diagnosis rates rose dramatically and preoperative planning became easier.
In 1985, J. Aidan Carney defined a familial syndrome combining cardiac myxoma, spotty skin pigmentation and endocrine overactivity, naming it the 'Carney complex.' This discovery was the first systematization of the involvement of genetic mechanisms in the development of myxoma and subsequently became a catalyst for molecular genetic research. In the 2000s, as inactivating variants of the PRKAR1A gene were identified as the main cause of Carney complex, the clinical importance of genetic counseling and family screening came to the fore.
In the 21st century, the soft-tissue resolution and tissue characterization capability of cardiac MRI, together with CT, have become established as adjunctive diagnostic tools, and the development of minimally invasive cardiac surgery is lowering surgical risk further. Currently, the 30-day mortality after surgical treatment of cardiac myxoma is less than 1%, and long-term survival has improved to a level similar to that of the general population.
Benign neoplasms of the heart are broadly divided by mechanism of development into sporadic and hereditary forms. About 95% of all cardiac myxomas occur sporadically, and in most cases no clear external risk factor is identified. Sporadic myxomas are understood to originate from primitive multipotent mesenchymal cells of the endocardium, and the tumor forms as these cells proliferate abnormally and produce a myxoid stroma.
The representative hereditary cause is Carney complex, which accounts for about 7% of all cardiac myxomas. Inactivating variants of the PRKAR1A gene (encoding protein kinase A regulatory subunit 1-alpha) are the main molecular cause; this gene is a key regulator of the cAMP-dependent signaling pathway, and when it is mutated, the function of suppressing cell proliferation is lost. In addition, abnormalities in the chromosome 2p15-16 region have been reported in some familial cases.
Histologically, myxoma cells are presumed to derive from multipotent primitive endocardial cells capable of differentiating into vascular endothelial cells, smooth muscle cells and fibroblasts. These cells are concentrated mainly in the atrial septum around the fossa ovalis, so myxoma occurs most frequently at this site. Growth factors and cytokines (VEGF, IL-6, bFGF, etc.) are known to be involved in tumor angiogenesis and growth.
Causes of benign cardiac tumors other than cardiac myxoma include rhabdomyoma associated with tuberous sclerosis (TSC1/TSC2 gene variants) and lipoma associated with Gaucher disease and Hunter syndrome. For papillary fibroelastoma, endocardial trauma or degenerative changes have been proposed as triggering factors.
The most important element of the genetic background of benign cardiac neoplasms is the molecular genetic abnormality associated with Carney complex. The main causative gene is PRKAR1A (protein kinase A regulatory subunit 1-alpha), located on chromosome 17q22-24; inactivating variants of this gene (mainly frameshift or nonsense variants) are found in more than 70% of all patients with Carney complex. PRKAR1A acts as a negative regulator of the cAMP signaling pathway, and when the gene is damaged, PKA activity persists and cell proliferation is not suppressed.
Carney complex follows an autosomal dominant mode of inheritance, and when it occurs within families, about 70% show a family history. In patients carrying a germline mutation, tumors arise at the somatic level through loss of the second allele (two-hit model). The second genetic locus, in which variants are found in 19% of patients with Carney complex, is chromosome 2p15-16; the associated gene has not yet been fully identified, but it is characterized by overlapping expression with PPNAD (primary pigmented nodular adrenocortical disease).
In sporadic myxoma, genetic abnormalities arise at the somatic level without a specific germline variant, and variants in classic tumor-related genes such as IDH1, KRAS and TP53 are rare. Recent studies have observed reduced PRKAR1A protein expression in sporadic myxomas as well, suggesting involvement of the same pathway. Rhabdomyoma is caused by variants in the TSC1 (9q34, encoding the hamartin protein) or TSC2 (16p13, encoding the tuberin protein) gene, with mTOR signaling hyperactivation as the key mechanism.
Genetic testing should be actively performed in patients suspected of having Carney complex, especially with onset before age 35, multiple or recurrent myxomas, or accompanying extracardiac features (pigmentary skin abnormalities, endocrine tumors, etc.). When a germline variant of the PRKAR1A gene is confirmed, screening echocardiography and genetic counseling are recommended for first-degree relatives.
Benign neoplasms of the heart are the most frequent of the primary cardiac tumors. The overall prevalence of primary cardiac tumors is reported as 0.001–0.28% in autopsy studies, of which about 75% are benign. Myxomas account for more than 50% of benign cardiac tumors, and the incidence of clinically significant cardiac myxoma is estimated at about 0.5–1 per million per year.
Cardiac myxoma occurs about 2–3 times more often in women than in men, with a peak age of onset in the 30s–60s. About 75% arise in the left atrium and about 20–25% in the right atrium, while ventricular origin is rare (less than 5%). About 80% of left atrial myxomas grow in pedunculated form from the atrial septum near the fossa ovalis.
Unlike sporadic myxomas, Carney complex-associated myxomas also commonly appear in young people in their 20s–30s, show little difference in frequency between the sexes, and are relatively more often multiple (biventriculat, biventricular, biatrial) or of ventricular origin. In this patient group, the proportion developing myxoma by age 30 reaches about 45% in men and about 35% in women.
Other benign cardiac tumors include papillary fibroelastoma (the second most common, occurring mainly on the valves), rhabdomyoma (the most common cardiac tumor in children), fibroma and hemangioma. According to population-based studies, the overall frequency of surgical resection of primary cardiac tumors is increasing, owing to the wider availability of echocardiography and cardiac imaging.
Data on regional and ethnic differences are limited, but cardiac myxoma is reported evenly worldwide. In Korea, analysis of health insurance claims data shows that several hundred cardiac myxoma operations are performed each year, and early diagnosis and safe surgical outcomes continue to improve.
The pathogenesis of cardiac myxoma begins with neoplastic transformation of primitive multipotent mesenchymal cells of the endocardium. These cells normally remain at the margin of the fossa ovalis and have the potential to differentiate into various cell lineages. When negative regulation of the cAMP-PKA signaling pathway is lost, for example through inactivation of the PRKAR1A gene, the balance between cell proliferation and differentiation is disrupted and a population of tumor cells forms.
During tumor growth, growth factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and interleukin-6 (IL-6) play key roles. Excessive secretion of IL-6 causes a systemic inflammatory response (fever, weight loss, elevated CRP) and anemia, the so-called 'myxoma syndrome.' VEGF-driven angiogenesis contributes to the formation of abundant vascular structures on the tumor surface, and because these vessels are structurally fragile, spontaneous hemorrhage or thrombus formation may occur.
The gross structure of the tumor is in most cases a pedunculated mass arising from the atrial septum near the fossa ovalis, gelatinous or grape-like in form. The main complication is detachment of thrombotic fragments from the surface, causing systemic or pulmonary embolism, which results in serious neurological damage especially when it takes the form of cerebral embolism. Large tumors can intermittently obstruct the mitral orifice, causing position-dependent hemodynamic abnormalities and syncope.
Histologically, myxoma cells are scattered in stellate or spindle shapes within a myxoid stroma rich in acid mucopolysaccharides (glycosaminoglycans) and tend to cluster around blood vessels. Some tumors show accompanying secondary changes such as iron-containing pigment (hemosiderin), calcification and cystic change.
The clinical symptoms of cardiac myxoma vary with tumor size, location, mobility and whether embolism occurs. They are typically classified into three categories: obstructive symptoms, embolic symptoms and constitutional symptoms.
Obstructive symptoms are most prominent in left atrial myxoma and present in a manner mimicking mitral stenosis. Dyspnea (especially exertional dyspnea) is most common, reported in about 64.5% of patients. When the tumor intermittently obstructs the mitral orifice, symptoms characteristically change with position, and syncope or dizziness may occur suddenly in certain postures. In severe cases this can lead to pulmonary edema and acute heart failure.
Embolic symptoms occur in about 30–40% of all patients, of which cerebrovascular embolism (stroke or transient ischemic attack) is the most serious complication. Because myxoma is not uncommonly found when echocardiography is performed in patients with cardioembolism, it must be considered in young stroke patients. Acute myocardial infarction due to coronary embolism and lower-limb ischemia due to peripheral arterial embolism have also been reported.
Constitutional symptoms include fever, weight loss, fatigue and arthralgia, which result from a systemic inflammatory response due to IL-6 secreted by the tumor. Blood tests may show elevated CRP, increased erythrocyte sedimentation rate (ESR), anemia, leukocytosis and thrombocytopenia. Because these nonspecific systemic symptoms can be confused with rheumatic disease or infective endocarditis, caution is needed.
On physical examination, cardiac myxoma can show several characteristic signs. The most typical auscultatory finding is the tumor plop, a low-pitched, strong sound heard 0.08–0.12 seconds after the second heart sound (S2), produced the moment the tumor drops to the level of the mitral valve. This finding appears later than the opening snap of mitral stenosis and characteristically varies in intensity with change of position.
Depending on the size and location of the tumor, a murmur of mitral stenosis or mitral regurgitation may be heard, varying with change of position. In right atrial myxoma, a murmur mimicking tricuspid stenosis may be heard. If pulmonary hypertension has developed, an accentuated pulmonic closure sound (P2 accentuation) is observed.
Systemic findings may include spotty skin pigmentation (lentigines), mucosal pigmentation and blue nevi when Carney complex is present. When chronic heart failure is present, signs of right heart failure such as jugular venous distension, hepatomegaly and lower-limb edema appear. In patients with embolic complications, focal neurological deficits, absent lower-limb pulses and ischemia of the fingertips and toes may be observed. When prolonged hypoxemia or pulmonary hypertension due to chronic embolism persists, clubbing of the fingers and toes may also appear.
A systematic population screening program for benign cardiac neoplasms is currently not recommended, but targeted screening of high-risk groups is clinically important. The most important screening targets are patients diagnosed with Carney complex and their first-degree relatives. In this group, follow-up transthoracic echocardiography (TTE) once or twice a year from the time of diagnosis is recommended.
In carriers of confirmed germline PRKAR1A variants, regular echocardiographic surveillance is essential even in the asymptomatic phase. Given reports that the mean age at first myxoma in patients with Carney complex is in the late 20s, it is reasonable to begin screening from adolescence after a germline variant is confirmed.
In terms of symptom-based screening, echocardiography should be performed in all patients with unexplained stroke or systemic embolism (especially young patients), an intermittent heart murmur that varies with position, or cardiac symptoms accompanied by signs of systemic inflammation. When a tumor is found or suspected on echocardiography, further evaluation is done with transesophageal echocardiography (TEE), cardiac CT or MRI. In addition, for familial or adolescent onset and recurrent or multiple myxomas, genetic evaluation including PRKAR1A genetic testing is actively recommended.
The diagnosis of cardiac myxoma is based on imaging. Transthoracic echocardiography (TTE) is the first-line diagnostic tool; it is highly sensitive and noninvasive and can rapidly establish the presence, size, attachment site and valvular relationship of a mobile mass in the left atrium. A mobile mass on TTE together with an auscultated tumor plop strongly suggests myxoma.
Transesophageal echocardiography (TEE) has superior spatial resolution compared with TTE and can evaluate the attachment site, margins and internal structure of the tumor (homogeneity, admixed thrombus) more precisely. It is essential particularly when the diagnosis on TTE is uncertain or when precise determination of tumor size and location is needed for surgical planning.
Cardiac CT is useful for evaluating the density characteristics of the tumor (low attenuation of the myxoid stroma), calcification, degree of vascularization and relationship to surrounding structures. On CT, myxoma typically appears as a spherical or oval low-density mass, with mild or heterogeneous enhancement after contrast.
Cardiac MRI has the best soft-tissue resolution, showing intermediate signal intensity on T1-weighted images and high signal intensity on T2-weighted images, which helps characterize soft-tissue components. Analysis of the late gadolinium enhancement pattern after gadolinium contrast can be used to differentiate it from malignant tumors.
Definitive diagnosis is made by histopathological examination after surgical resection. The diagnostic criteria are the typical morphology of myxoma cells, myxoid stroma and the presence of vascular structures. On immunohistochemistry, Calretinin positivity is used as a relatively specific marker of myxoma cells. Percutaneous approaches for biopsy are generally avoided because of the risk of embolism.
The standard treatment for cardiac myxoma is complete surgical resection. The principle is to operate immediately upon diagnosis, to preempt the risk of embolic complications and sudden hemodynamic collapse. Surgery is performed under general anesthesia with the heart arrested using cardiopulmonary bypass, and securing adequate resection margins that widely include the tumor's base of origin is important for preventing recurrence.
The surgical approaches mainly used are right thoracotomy or median sternotomy. Recently, minimally invasive cardiac surgery, particularly resection via right mini-thoracotomy, has been applied at some centers, with reported advantages in cosmetic and functional recovery. For a single tumor, simple tumor extirpation suffices in about 65.8%, while reconstruction is needed when the adjacent atrial septum or valves are involved.
Postoperative management includes early ambulation, appropriate anticoagulation (especially when atrial fibrillation is present) and periodic echocardiographic follow-up. Because the postoperative recurrence rate of sporadic myxoma is about 1–3%, regular follow-up is recommended. Because Carney complex-associated myxomas have a recurrence rate as high as 44%, these patients should maintain echocardiographic surveillance once or twice a year for life.
Drug therapy is limited to symptom relief (diuretics, anticoagulants), and no medical treatment for the tumor itself currently exists. When embolic complications such as stroke occur, standard stroke treatment in consultation with neurology should be given in the acute phase while surgical resection is planned as soon as possible. Thirty-day surgical mortality is very low, under 1%, at modern cardiac surgery centers.
After complete surgical resection, the long-term prognosis of cardiac myxoma is generally good. Postoperative 30-day mortality is reported to be under 1% with modern cardiac surgical techniques, and 5-year survival is similar to that of the age-matched general population. Symptoms improve rapidly after surgery, and hemodynamic abnormalities resolve almost immediately.
Recurrence is rare in sporadic myxoma, at only 1–3%, but postoperative recurrence rates of up to 44% have been reported for Carney complex-associated multiple myxomas, with most recurrences occurring within 8 years after surgery. Reoperation is recommended for recurrence, and the prognosis of repeat surgery is comparable to that of the first operation.
When embolic complications occur, neurological sequelae affect the long-term prognosis; in particular, multiple cerebral infarctions may leave permanent cognitive decline or physical paralysis. Early surgery immediately upon diagnosis is therefore critically important for preventing embolism. Acute myocardial infarction or sudden death due to coronary embolism is rare but can be fatal, so delaying surgery must be avoided.
There is currently no method of primary prevention for sporadic cardiac myxoma. However, for patients with Carney complex and family members carrying PRKAR1A gene variants, early detection through regular echocardiography (once or twice a year) is the de facto prevention strategy. Immediate surgery after early detection can prevent embolic complications.
A systematic surveillance program is needed in which first-degree relatives of patients with Carney complex are screened for PRKAR1A gene variants through genetic counseling, and echocardiographic follow-up begins from adolescence for those with a confirmed variant. In addition, when a tumor at high risk of embolism (large, highly mobile) is identified, temporary anticoagulation may be considered while awaiting surgery to prevent stroke.
To prevent postoperative recurrence, complete resection with adequate margins is most important. Regular postoperative echocardiographic follow-up (sporadic: once a year for 5 years; Carney complex: once or twice a year for life) helps with early detection of recurrence and with deciding the optimal timing of reoperation.
Butany J, Nair V, Naseemuddin A, et al. Cardiac tumours: diagnosis and management. Lancet Oncology. 2005;6(4):219-228. DOI: 10.1016/S1470-2045(05)70093-0. PMID: 15811617.
Silverman NA. Primary cardiac tumors. Annals of Surgery. 1980;191(2):127-138. DOI: 10.1097/00000658-198002000-00001. PMID: 7352797.
Carney JA, Gordon H, Carpenter PC, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985;64(4):270-283. DOI: 10.1097/00005792-198507000-00007. PMID: 4010357.
Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nature Genetics. 2000;26(1):89-92. DOI: 10.1038/79238. PMID: 10973256.
Grebenc ML, Rosado de Christenson ML, Burke AP, et al. Primary cardiac and pericardial neoplasms: radiologic-pathologic correlation. RadioGraphics. 2000;20(4):1073-1103. DOI: 10.1148/radiographics.20.4.g00jl081073. PMID: 10903697.
Pinede L, Duhaut P, Loire R. Clinical presentation of left atrial cardiac myxoma: a series of 112 consecutive cases. Medicine (Baltimore). 2001;80(3):159-172. DOI: 10.1097/00005792-200105000-00002. PMID: 11388092.
Araoz PA, Mulvagh SL, Tazelaar HD, et al. CT and MR imaging of benign primary cardiac neoplasms with echocardiographic correlation. RadioGraphics. 2000;20(5):1303-1319. DOI: 10.1148/radiographics.20.5.g00se121303. PMID: 10992019.
Meng Q, Lai H, Lima J, et al. Echocardiographic and pathologic characteristics of primary cardiac tumors: a study of 149 cases. International Journal of Cardiology. 2002;84(1):69-75. DOI: 10.1016/S0167-5273(02)00136-5. PMID: 12104067.
Centofanti P, Di Rosa E, Deorsola L, et al. Primary cardiac tumors: early and late results of surgical treatment in 91 patients. Annals of Thoracic Surgery. 1999;68(4):1236-1241. DOI: 10.1016/S0003-4975(99)00700-4. PMID: 10543487.
Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. Journal of Clinical Endocrinology and Metabolism. 2001;86(9):4041-4046. DOI: 10.1210/jcem.86.9.7903. PMID: 11549623.